Details of the Drug

General Information of Drug (ID: DMAY7H4)

Drug Name

Valdecoxib

Synonyms

Bextra; COX; Kudeq; Valdyn; Pfizer brand of valdecoxib; Valdecoxib [USAN]; SC 65872; ND-0214; SC-65872; YM-974; Valdecoxib (USAN/INN); P-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-(9CI); 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Osteoarthritis	FA00-FA05	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiinflammatory Agents

Affected Organisms

Humans and other mammals

ATC Code

M01AH03: Valdecoxib

M01AH: Coxibs

M01A: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

M01: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

M: MUSCULO-SKELETAL SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

314.4

Logarithm of the Partition Coefficient (xlogp)

2.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability: The bioavailability of drug is 83% []
Clearance: The apparent oral clearance of drug is 6 L/h []
Half-life: The concentration or amount of drug in body reduced by one-half in 8 - 11 hours [3]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.12173 micromolar/kg/day [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.02% [3]
Vd: The volume of distribution (Vd) of drug is 86 L []

Chemical Identifiers

Formula: C16H14N2O3S
IUPAC Name: 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide
Canonical SMILES: CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N
InChI: InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)
InChIKey: LNPDTQAFDNKSHK-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 119607
ChEBI ID: CHEBI:63634
CAS Number: 181695-72-7
UNII: 2919279Q3W
DrugBank ID: DB00580
TTD ID: D0L6DA
VARIDT ID: DR01196
INTEDE ID: DR1666

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[5]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[7]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[9]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[9]
Fibroblast growth factor 2 (FGF2)	OT7YUJ9F	FGF2_HUMAN	Protein Interaction/Cellular Processes	[10]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB)	OT17HGXJ	DMB_HUMAN	Gene/Protein Processing	[11]
HLA class II histocompatibility antigen, DP alpha 1 chain (HLA-DPA1)	OT7OG7Y2	DPA1_HUMAN	Gene/Protein Processing	[11]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Gene/Protein Processing	[12]
Vascular endothelial growth factor A, long form	OTIM9MZ3	VEGFA_HUMAN	Protein Interaction/Cellular Processes	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Osteoarthritis

ICD Disease Classification

FA00-FA05

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 2 (COX-2)	DTT	PTGS2	7.93E-04	-0.29	-0.34
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 138 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	5.9251	9.1567	5.6428	22.9695
MEC1	CTRP2	7.6162	9.5623	7.3677	11.6179
JM1	CTRP2	7.4402	9.4894	7.1999	12.7556
EoL-1	CTRP2	4.014	5.8688	4.0105	34.7201
Mono-Mac-6	CTRP2	4.324	13.3949	2.3589	37.6839
Ri-1	CTRP2	4.5755	11.4862	3.395	34.5061
KMS-34	CTRP2	4.7206	6.1403	4.7194	30.0093
KMS-12-BM	CTRP2	5.1506	8.1152	5.0253	27.5675
Mono-Mac-1	CTRP2	5.1902	8.1869	5.0559	27.3349
SK-MM-2	CTRP2	5.2123	9.0036	4.9049	27.7818
REC-1	CTRP2	5.2654	6.7405	5.2618	26.3914
Peer	CTRP2	5.3208	7.3311	5.2956	26.0953
SU-DHL-6	CTRP2	5.3664	8.3661	5.2139	26.2262
Pfeiffer	CTRP2	5.3705	6.3999	5.3702	25.681
KMS-21-BM	CTRP2	5.4298	7.5721	5.391	25.4155
697	CTRP2	5.4795	6.5051	5.4792	24.9555
MOLT-16	CTRP2	5.5153	6.9575	5.5107	24.7314
KMM-1	CTRP2	5.5364	11.6451	4.3542	28.6138
L-540	CTRP2	5.6008	7.6166	5.5662	24.2633
BL-70	CTRP2; CTRP1	5.6908	6.1576	5.6908	23.548
GA-10	CTRP2	5.7015	8.0641	5.6235	23.7409
U-937	CTRP2; CTRP1	5.7304	9.8101	5.2377	25.0076
SU-DHL-5	CTRP1	5.7766	7.1265	5.772	49.0478
Ku812	CTRP2; CTRP1	5.8914	7.9828	5.836	22.3998
OCI-Ly3	CTRP2	5.9236	10.1202	5.3442	24.045
KMS-18	CTRP2	5.9312	8.4492	5.809	22.3652
KE-37	CTRP2	5.9431	8.2398	5.8566	22.1622
BL-41	CTRP2	5.9771	10.3145	5.3339	23.9226
SUP-T11	CTRP2	5.9779	7.9773	5.9282	21.8049
Toledo	CTRP2	5.9919	10.3715	5.3295	23.8949
HPB-ALL	CTRP2	6.002	8.3133	5.9084	21.7949
RPMI-8402	CTRP2	6.0543	8.2732	5.9708	21.4124
RS4;11	CTRP2	6.0727	8.995	5.8453	21.7941
TALL-1 [Human adult T-ALL]	CTRP2	6.1128	9.1079	5.8605	21.6161
NALM-6	CTRP2	6.1714	8.7727	6.0047	20.9233
DEL	CTRP2	6.275	7.3723	6.2723	19.6691
THP-1	CTRP2; CTRP1	6.2757	8.2296	6.2137	19.8652
GDM-1	CTRP2; CTRP1	6.2955	8.5319	6.1874	19.8924
LP-1	CTRP2; CTRP1	6.3034	9.6426	5.9144	20.8444
NU-DUL-1	CTRP2; CTRP1	6.3048	8.6902	6.1671	19.9341
MOLM-16	CTRP2; CTRP1	6.3342	8.7953	6.1767	19.8081
KHM-1B	CTRP2	6.3562	9.2396	6.0909	20.0457
Ki-JK	CTRP2	6.3761	9.0241	6.169	19.7055
KM-H2	CTRP2	6.3792	8.4518	6.2914	19.2654
MM1.S	CTRP2	6.4137	8.6953	6.2841	19.1815
RCH-ACV	CTRP2	6.5263	8.493	6.4429	18.2715
BV-173	CTRP2	6.545	8.8111	6.4025	18.3533
PL21	CTRP2; CTRP1	6.5513	9.7146	6.161	19.2056
MOLT-3	CTRP2	6.5845	9.659	6.215	18.9092
OCI-AML-3	CTRP2; CTRP1	6.5916	9.0495	6.3976	18.2259
A4/Fukuda	CTRP2	6.619	8.5764	6.5286	17.6788
MOLM-13	CTRP2	6.6666	8.8445	6.5274	17.5331
JVM-3	CTRP2	6.7588	9.0191	6.5874	17.0338
Daudi	CTRP2	6.7605	8.9443	6.6071	16.9586
Mino	CTRP2	6.7634	8.6398	6.6732	16.7173
DB	CTRP2	6.7913	8.8398	6.6639	16.6621
RPMI-8226	CTRP1	6.7962	10.1636	6.2651	37.5241
KMS-11	CTRP1	6.8651	9.9288	6.4238	36.1967
SU-DHL-1	CTRP2	6.8776	8.9149	6.7413	16.1194
Karpas-299	CTRP2	6.8867	9.2094	6.678	16.3172
KMS-20	CTRP2	6.8961	9.3455	6.6502	16.3892
P12-Ichikawa	CTRP2	6.8968	10.1787	6.3733	17.413
MOLM-6	CTRP2	6.9358	9.7831	6.5558	16.6182
HH [Human lymphoma]	CTRP2	6.9488	9.2507	6.7345	15.9248
EB1	CTRP2	6.9636	9.3644	6.7184	15.9384
MC116	CTRP2; CTRP1	7.0004	9.1782	6.8106	15.4936
Jurkat	CTRP2	7.0314	9.5764	6.7275	15.7029
A3/Kawakami	CTRP2	7.0973	9.3314	6.8739	14.9709
NCO2	CTRP2	7.0982	9.1607	6.9219	14.7951
L-428	CTRP2	7.1173	9.7029	6.7795	15.2582
SU-DHL-4	CTRP2; CTRP1	7.1324	10.1892	6.622	15.806
SU-DHL-8	CTRP2	7.1564	9.2315	6.9664	14.4573
CML-T1	CTRP2	7.2078	9.3275	6.9955	14.1967
OPM-2	CTRP2	7.2096	10.9153	6.4127	16.3969
KCL-22	CTRP2	7.2182	10.7435	6.4933	16.0616
L-363	CTRP2	7.2197	8.8431	7.1282	13.6862
K-562	CTRP2	7.2317	9.2923	7.0316	13.9938
TF-1	CTRP2	7.24	9.2377	7.0559	13.8805
CA46	CTRP2	7.2763	9.7009	6.9527	14.151
ST486	CTRP2	7.3046	9.3909	7.0824	13.5896
F-36P	CTRP2	7.3156	9.6124	7.0248	13.7684
JURL-MK1	CTRP2	7.3588	10.6881	6.6636	15.0214
PF-382	CTRP2	7.3865	9.1698	7.234	12.7931
MHH-CALL-3	CTRP2	7.395	9.6779	7.0891	13.298
KYO-1	CTRP2	7.4355	10.1885	6.9459	13.723
SKM-1	CTRP1	7.4473	10.2382	6.9327	28.9272
NOMO-1	CTRP1	7.4648	9.2169	7.3035	26.1184
HEL	CTRP2	7.4769	10.0585	7.0401	13.2483
KMS-26	CTRP2	7.479	8.7258	7.4293	11.8152
HT	CTRP2; CTRP1	7.4842	9.2164	7.3282	12.1565
EM-2	CTRP2	7.4874	9.9895	7.0773	13.0773
Kasumi-1	CTRP2	7.5061	9.9896	7.0974	12.9482
OCI-AML-5	CTRP2	7.5402	9.159	7.4045	11.7114
JeKo-1	CTRP2	7.5439	9.3877	7.3443	11.9179
HEL 92.1.7	CTRP2	7.5541	9.2499	7.3954	11.7016
Namalwa	CTRP2	7.5591	9.9351	7.1746	12.5059
LAMA-84	CTRP2	7.5718	9.9656	7.1767	12.4619
CMK	CTRP2	7.5741	9.8395	7.2259	12.2693
KE-97	CTRP2; CTRP1	7.5852	9.1424	7.4579	11.3822
HD-MY-Z	CTRP2	7.6167	9.4478	7.4051	11.4788
OCI-Ly19	CTRP2	7.6223	12.6871	6.0289	16.8483
Karpas-620	CTRP2	7.6236	9.7743	7.3027	11.8391
EJM	CTRP2; CTRP1	7.6969	11.4717	6.6682	14.1197
SET-2	CTRP2	7.6974	10.1309	7.247	11.8427
SUP-M2	CTRP2	7.7029	10.1148	7.2592	11.7807
RL	CTRP2	7.7129	9.6847	7.4309	11.1014
Karpas-422	CTRP2	7.7268	9.4428	7.5265	10.7063
Raji	CTRP2	7.7302	9.5744	7.4874	10.8407
P3HR-1	CTRP2; CTRP1	7.7329	11.1705	6.8407	13.3413
SUP-HD1	CTRP2	7.7437	10.186	7.2741	11.6109
WSU-DLCL2	CTRP2; CTRP1	7.7512	8.6772	7.7266	9.9177
HL-60	CTRP2	7.7699	9.4604	7.5679	10.4266
HDLM-2	CTRP2	7.7765	10.6464	7.1162	12.1379
DND-41	CTRP2	7.778	10.6	7.1377	12.0497
U266B1	CTRP2	7.8019	9.6887	7.5256	10.4904
MHH-CALL-4	CTRP2	7.8222	9.8179	7.5004	10.5272
NCI-H929	CTRP2	7.8988	9	7.8328	9.0791
ME1	CTRP2	7.9219	10.4324	7.3586	10.8017
P31/FUJ	CTRP2	7.9301	9.5238	7.7212	9.3892
HuT 78	CTRP2	8.0033	10.3487	7.4789	10.1141
Kasumi-2	CTRP2	8.0107	10.9093	7.2394	11.044
MOLP-2	CTRP2	8.1354	11.114	7.2705	10.6071
Granta-519	CTRP2	8.1598	13.3014	6.245	14.7162
AMO1	CTRP2; CTRP1	8.1694	9.6519	7.9347	7.8999
JJN-3	CTRP2	8.2049	9.8945	7.8789	8.0139
MOLP-8	CTRP2	8.2488	9.3175	8.1338	6.9277
EHEB	CTRP2	8.2596	12.4563	6.7501	12.434
AML-193	CTRP2	8.2905	9.2459	8.2	6.5619
NU-DHL-1	CTRP2	8.3239	10.0116	7.9553	7.3952
SUP-B15	CTRP2	8.3682	10.313	7.8696	7.6179
KO52	CTRP2	8.3747	11.4299	7.3549	9.687
SEM	CTRP2	8.3848	9.4664	8.2334	6.1602
SIG-M5	CTRP2	8.4491	9.4581	8.3058	5.7036
OCI-Ly10	CTRP2; CTRP1	8.4768	14.4195	5.9829	15.062
OCI-M1	CTRP2	8.4769	9.7264	8.2339	5.8988
RPMI-6666	CTRP2	8.4965	9.4025	8.3762	5.3035
MOTN-1	CTRP2	8.5556	9.8661	8.258	5.5931
Hs 611.T	CTRP2	8.666	9.8703	8.3699	4.8629
-----------


⏷ Show the Full List of 138 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE15	CTRP2	8.0599	10.0453	7.6647	9.2376
TE8	CTRP2	8.4594	11.7642	7.2741	9.8227
EC-GI-10	CTRP2	6.9199	10.5408	6.2598	17.7778
KYSE-410	CTRP2; CTRP1	7.3656	10.1962	6.8685	14.2136
KYSE-70	CTRP2	7.3959	9.25	7.2227	12.8054
TE-6	CTRP2	7.5003	9.9018	7.1237	12.8653
TE-11	CTRP2	7.5677	9.6353	7.2907	12.0452
KYSE-140	CTRP2; CTRP1	7.6415	11.1107	6.7744	13.8396
TE-1	CTRP2	7.6796	11.3588	6.702	14.029
KYSE-30	CTRP2	7.7952	9.262	7.6551	10.0323
TE-4	CTRP2	7.8128	11.4161	6.8098	13.2623
TE-9	CTRP2	7.9325	9.8366	7.6116	9.7943
TE-14	CTRP2	8.13	10.7323	7.4399	9.9401
TE-5	CTRP2	8.1882	10.6605	7.5311	9.4277
OE21	CTRP2	8.2011	9.9376	7.8574	8.1073
KYSE-150	CTRP2	8.3984	11.6401	7.2765	9.9533
KYSE-520	CTRP2	8.4212	12.0645	7.0922	10.6592
OE19	CTRP2	8.4823	10.0291	8.1118	6.3622
OE33	CTRP2	8.4829	12.7926	6.7926	11.7566
TE-10	CTRP2	8.4996	10.0217	8.1329	6.2334
KYSE-510	CTRP2	8.5044	11.5086	7.4405	9.0338
COLO 680N	CTRP2	8.5326	11.9826	7.2359	9.8145
KYSE-450	CTRP2; CTRP1	8.5757	12.5574	6.9932	10.724
KYSE-180	CTRP2	8.9103	14.1374	6.5043	12.0376
-----------


⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	7.9154	9.5302	7.7031	9.4993
PaTu 8988s	CTRP2	6.8896	10.8034	6.1229	18.3834
YAPC	CTRP2	7.7127	9.3926	7.5267	10.7474
PSN1	CTRP2	7.751	9.8964	7.3947	11.1292
PK-45H	CTRP2	7.7577	13.3698	5.8333	17.2903
L3.3	CTRP2	7.8606	10.8303	7.1224	11.8941
BxPC-3	CTRP2	7.9322	11.3794	6.9458	12.4185
HuP-T4	CTRP2; CTRP1	7.9473	10.0772	7.5331	10.054
HPAF-II	CTRP2	7.9665	11.1032	7.1069	11.6861
KP-4	CTRP2	7.9758	9.8761	7.6427	9.5542
MIA PaCa-2	CTRP2	7.9983	9.7709	7.7068	9.2472
SW1990	CTRP2	8.0015	10.5135	7.4059	10.4061
SU.86.86	CTRP2	8.0191	9.4594	7.8391	8.6916
SNU-410	CTRP2	8.0633	9.616	7.8335	8.5839
KP-3	CTRP2; CTRP1	8.1797	11.1052	7.3184	10.3045
HPAC	CTRP2; CTRP1	8.2169	9.9571	7.8661	8.0307
Panc 10.05	CTRP2; CTRP1	8.3164	9.9312	7.9812	7.3144
TCC-Pan2	CTRP2	8.3358	9.9175	8.0073	7.1606
QGP-1	CTRP2; CTRP1	8.3513	9.8548	8.0493	6.9557
HuP-T3	CTRP2	8.412	13.798	6.2322	14.2031
SNU-213	CTRP2	8.4124	20.3294	2.9843	25.3029
Hs 766T	CTRP2	8.4287	13.4064	6.4408	13.3195
DAN-G	CTRP2	8.448	9.8141	8.1677	6.2339
Capan-1	CTRP2	8.4544	10.1531	8.0286	6.764
Panc 04.03	CTRP2	8.4667	11.8564	7.2361	9.9628
KP-2	CTRP2	8.4892	12.1518	7.113	10.4201
Panc 08.13	CTRP2	8.5213	9.8463	8.2309	5.7908
CFPAC-1	CTRP2; CTRP1	8.5256	10.5885	7.9007	7.0998
SUIT-2	CTRP2; CTRP1	8.5401	9.3378	8.4449	4.9215
PK-59	CTRP2	8.6016	13.658	6.472	12.8165
Capan-2	CTRP2; CTRP1	8.7378	11.6698	7.5784	7.9393
PaTu 8988t	CTRP2	8.8444	9.2535	8.8023	2.7066
Panc 02.03	CTRP2	8.928	14.6147	6.2812	12.9123
AsPC-1	CTRP2	8.9492	16.5301	5.3426	16.5489
PaTu 8902	CTRP2; CTRP1	9.1683	10.0868	8.7484	2.137
Panc 03.27	CTRP2; CTRP1	9.2833	12.7862	7.4953	7.1744
Panc 05.04	CTRP2	10.8979	24.1189	3.1249	20.1651
-----------


⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 49 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH4	CTRP2	10.0522	21.7723	3.6293	20.1995
COLO 792	CTRP2	5.8609	8.4247	5.7374	22.8374
G-361	CTRP2; CTRP1	6.1327	8.2043	6.0645	20.838
WM266-4	CTRP2	6.188	7.5202	6.18	20.2658
Malme-3M	CTRP2	6.8864	9.6002	6.5622	16.7398
Hs 852.T	CTRP2; CTRP1	6.9735	8.7974	6.8705	15.3641
WM115	CTRP2	6.9758	8.8316	6.866	15.3726
SK-MEL-5	CTRP2; CTRP1	7.0725	8.7324	6.9902	14.6332
Hs 944.T	CTRP2; CTRP1	7.0873	9.1818	6.9044	14.891
CJM [Human melanoma]	CTRP2	7.7063	9.8331	7.3704	11.3477
LOX-IMVI	CTRP2	7.8603	10.0904	7.4357	10.6682
MeWo	CTRP2	7.9819	10.6551	7.3237	10.7821
MDA-MB-435S	CTRP2	8.0293	9.952	7.67	9.3014
SK-MEL-31	CTRP2	8.0788	9.4906	7.8936	8.3149
UACC-62	CTRP2	8.1326	10.6612	7.4745	9.795
WM88	CTRP2	8.175	9.6711	7.9336	7.8878
Hs 940.T	CTRP2	8.2202	11.8955	6.9837	11.5694
Hs 936.T	CTRP2; CTRP1	8.2365	11.159	7.3493	10.0402
SK-MEL-1	CTRP1	8.2489	9.1488	8.1771	14.2574
Mel Ho	CTRP2	8.2876	9.2659	8.1913	6.6023
HMCB	CTRP2	8.2939	9.5297	8.113	6.8728
UACC-257	CTRP2	8.3074	10.9115	7.5348	9.1158
WM793	CTRP2	8.3469	11.9601	7.0731	10.908
RPMI-7951	CTRP2	8.3847	9.6785	8.155	6.4568
HT-144	CTRP2	8.3951	10.045	8.015	6.9721
COLO 741	CTRP2; CTRP1	8.4199	11.2791	7.4705	9.107
Mel JuSo	CTRP2	8.4245	12.8097	6.7307	12.1409
RVH-421	CTRP2	8.4394	9.7655	8.1785	6.2157
SK-MEL-3	CTRP2	8.4394	9.8315	8.1515	6.3201
SK-MEL-28	CTRP2; CTRP1	8.4532	8.8968	8.4447	5.1908
IGR-37	CTRP2	8.4629	9.3675	8.3513	5.4941
A-375	CTRP2; CTRP1	8.4634	9.0524	8.4342	5.1943
K029AX	CTRP2	8.4727	11.4996	7.4149	9.2124
IPC-298	CTRP2	8.4909	9.1716	8.4383	5.0938
SK-MEL-24	CTRP2	8.4969	13.1888	6.61	12.4773
WM983B	CTRP2	8.5154	12.5563	6.9386	11.0824
COLO 800	CTRP2	8.5242	9.6181	8.3271	5.41
Hs 895.T	CTRP2	8.6224	9.2062	8.5731	4.2079
SK-MEL-30	CTRP2	8.6296	9.1311	8.5987	4.0944
COLO 829	CTRP2	8.6383	9.7318	8.4011	4.8128
Hs 688(A).T	CTRP2	8.6612	9.1407	8.631	3.882
WT2-iPS	CTRP2	8.7068	9.1681	8.6744	3.5864
Hs 294T	CTRP2	8.742	10.0764	8.3531	4.738
A101D	CTRP2	8.7848	9.1436	8.7645	3.025
A2058	CTRP2	8.8173	9.1714	8.7939	2.8196
Hs 839.T	CTRP2	8.8306	9.1498	8.813	2.7106
IGR-39	CTRP2	9.1629	9.8253	8.874	1.6224
IGR-1	CTRP2	10.0879	19.4492	4.8157	16.2668
WM1799	CTRP2	12.5311	27.122	2.8627	18.2859
-----------


⏷ Show the Full List of 49 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	CTRP2	7.2474	11.2238	6.3202	16.6555
-----------

Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NB1	CTRP2	6.1979	7.5806	6.1878	20.2065
KP-N-YN	CTRP2	6.8284	9.0429	6.6575	16.5695
CHP-212	CTRP2	7.6251	9.6485	7.3484	11.6635
MHH-NB-11	CTRP2	8.126	14.4304	5.6601	17.1091
NH-6	CTRP2	8.354	9.2924	8.256	6.1673
SK-N-BE(2)	CTRP2	8.3674	10.4738	7.7963	7.9127
CHP-126	CTRP2	8.4711	9.5714	8.2883	5.7069
SK-N-AS	CTRP2	8.5009	9.4978	8.3476	5.3976
SK-N-SH	CTRP2	8.5287	10.0627	8.1446	6.1118
SK-N-DZ	CTRP2	8.7325	9.2275	8.6876	3.4603
-----------


⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-1079	CTRP2	5.5519	7.8073	5.4963	24.66
SNU-1196	CTRP2	6.4174	9.1245	6.1885	19.5088
HuCC-T1	CTRP2	7.6654	11.146	6.7831	13.7432
HuH-28	CTRP2	8.296	9.383	8.1649	6.6736
SNU-308	CTRP2	8.4025	10.2605	7.928	7.2975
SNU-869	CTRP2	8.5804	13.1814	6.6892	11.97
-----------


⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SK-N-MC	CTRP2	6.8821	9.0982	6.7022	16.2446
U2OS	CTRP2	7.3393	16.2187	4.0567	24.637
HOS	CTRP2	7.4119	9.7866	7.0699	13.3206
MHH-ES-1	CTRP2	7.6123	10.2837	7.0959	12.6588
A-673	CTRP2	7.6569	9.2308	7.5128	10.9657
SK-ES-1	CTRP2	8.1279	10.1408	7.6965	8.9305
CAL-78	CTRP2	8.3421	58.6679	-16.2335	42.8805
SaOS-2	CTRP2	8.4125	12.5848	6.8299	11.7598
SJSA-1	CTRP2	8.4331	9.8319	8.1447	6.3634
TC71	CTRP2	8.4811	9.7104	8.2448	5.8455
SW1353	CTRP2	8.4996	13.9833	6.2195	14.0634
Hs 822.T	CTRP2	8.6045	9.065	8.5842	4.2242
G-292 clone A141B1	CTRP2	8.6462	9.4566	8.5189	4.3377
Hs 888.T	CTRP2	8.7744	9.3612	8.6914	3.3222
MG-63	CTRP2	8.9104	14.9517	6.0979	13.6879
-----------


⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 70 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
DU4475	CTRP2	5.7119	7.5321	5.6885	23.4863
Hs 578T	CTRP2	5.9378	11.1285	4.9853	25.2822
HCC1143	CTRP2	6.0781	10.7972	5.2635	23.8799
MDA-MB-453	CTRP2	6.3776	9.2383	6.1146	19.8957
HCC1500	CTRP2	6.8417	10.6339	6.1401	18.4508
HCC2218	CTRP2	6.8576	8.5847	6.7842	16.0322
ZR-75-30	CTRP2	6.9249	9.5108	6.6321	16.3689
HCC1569	CTRP2	7.2482	9.1749	7.0818	13.7627
HCC202	CTRP2	7.2916	11.713	6.1498	17.2054
MCF-7	CTRP2; CTRP1	7.3724	10.8907	6.5926	15.2609
HCC1419	CTRP2	7.4111	10.1687	6.9277	13.8608
HMC-1-8	CTRP2	7.5874	9.8655	7.2307	12.2134
MDA-MB-468	CTRP2	7.6044	10.2132	7.1158	12.6038
AU565	CTRP2	7.6272	11.1651	6.7357	14.0297
BT-20	CTRP2	7.6321	10.8837	6.8644	13.5087
T-47D	CTRP2	7.7448	13.1519	5.9257	16.9586
HCC1954	CTRP2	7.7929	10.5347	7.1811	11.84
BT-474	CTRP2	7.9031	9.6445	7.6505	9.7309
HCC1937	CTRP2	7.905	9.8922	7.561	10.064
HCC1395	CTRP2	7.9542	10.6776	7.2855	11.0052
HCC1428	CTRP2	8.0262	10.7271	7.337	10.6151
CAL-51	CTRP2	8.0611	10.736	7.3685	10.4003
SK-BR-3	CTRP2	8.1202	10.584	7.4965	9.7393
ZR-75-1	CTRP2	8.1243	10.3666	7.5963	9.3333
MDA-MB-157	CTRP2	8.138	16.4505	4.673	20.7186
CAMA-1	CTRP2	8.1918	9.9145	7.8569	8.1345
MDA-MB-361	CTRP2	8.2495	17.2725	4.3643	21.5185
EFM-192A	CTRP2	8.354	9.6506	8.133	6.6265
KPL-1	CTRP2	8.3871	24.6947	0.7837	30.3053
CAL-85-1	CTRP2	8.4361	10.2695	7.958	7.0921
BT-549	CTRP2	8.437	10.9722	7.6333	8.4012
MDA-MB-415	CTRP2	8.4529	13.7304	6.3027	13.8282
JIMT-1	CTRP2	8.4922	13.1558	6.622	12.4383
Hs 578Bst	CTRP2	8.5238	11.3025	7.5586	8.503
MDA-MB-231	CTRP2	8.548	15.7903	5.3648	17.3078
HCC38	CTRP2	8.6156	10.3897	8.0823	6.1438
CAL-120	CTRP2	8.7284	9.1681	8.698	3.4355
HCC1806	CTRP2	9.6337	15.7978	6.2753	11.5675
BT147	CTRP2	7.0996	10.4846	6.4728	16.466
BT 416	CTRP2	7.3006	9.5673	7.0232	13.8186
BT 231	CTRP2	7.4229	10.1736	6.9384	13.787
BT 248	CTRP2	7.5229	10.2706	7.0066	13.2483
BT 172	CTRP2	7.9637	10.4252	7.4051	10.5085
BT 245	CTRP2	7.993	9.9343	7.6384	9.523
BT 232	CTRP2	8.344	12.2913	6.9096	11.5866
BT 498	CTRP2	8.3621	10.5431	7.7594	8.074
BT 145	CTRP2	8.3901	10.5327	7.7922	7.8723
BT 286	CTRP2	8.4358	9.8045	8.1588	6.3017
BT164	CTRP2	8.46	9.5782	8.2739	5.7926
BT 444	CTRP2	8.4752	10.1675	8.0434	6.6517
BT 112	CTRP2	8.5259	9.6494	8.3166	5.4456
BT 422	CTRP2	8.5622	10.3358	8.0545	6.3876
BT 359	CTRP2	8.5791	10.3397	8.0695	6.2853
BT 228	CTRP2	8.5974	9.2189	8.5425	4.3941
BT 271	CTRP2	8.5983	9.3019	8.5194	4.4752
BT 440	CTRP2	8.6171	9.3852	8.5128	4.4445
BT 330	CTRP2	8.6375	9.2638	8.5736	4.1599
BT 216	CTRP2	8.6381	10.4968	8.0539	6.205
BT 179	CTRP2	8.664	9.1614	8.6294	3.8789
BT 159	CTRP2	8.6709	9.1157	8.6467	3.7962
BT 504	CTRP2	8.6777	9.2026	8.6343	3.8191
BT 131	CTRP2	8.7434	9.5281	8.5953	3.7744
BT 139	CTRP2	8.7823	9.3146	8.7157	3.2088
BT 328	CTRP2	8.8235	9.7188	8.5978	3.5514
BT 482	CTRP2	8.8596	9.59	8.6914	3.0872
BT 333	CTRP2	8.9153	9.8552	8.6272	3.2041
BT 239	CTRP2	8.9295	9.7738	8.6793	2.9581
BT 340	CTRP2	8.989	10.3212	8.4718	3.6736
BT 320	CTRP2	9.1385	10.1986	8.6667	2.5407
BT 224	CTRP2	10.3467	16.7238	6.3672	9.9517
-----------


⏷ Show the Full List of 70 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	8.7663	9.2969	8.7039	3.2995
-----------

Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
T98G	CTRP2	6.1604	9.8738	5.6842	22.109
TM-31	CTRP2	6.6599	8.5108	6.5836	17.3577
8-MG-BA	CTRP2	7.4768	9.7076	7.1675	12.7686
SW1088	CTRP2	7.5478	13.4526	5.5927	18.7286
SW1783	CTRP2	7.5481	10.2876	7.0265	13.1024
KNS-42	CTRP2	7.7527	9.3604	7.5801	10.433
D283 Med	CTRP2	7.8447	9.72	7.5606	10.2361
SF268	CTRP2	7.8663	11.1939	6.9649	12.5072
Daoy	CTRP2	7.8723	11.8581	6.6638	13.7018
KALS-1	CTRP2	7.9772	12.5997	6.4131	14.4614
KNS-60	CTRP2	8.0357	9.9743	7.6678	9.2921
SF539	CTRP2	8.1289	11.443	7.1103	11.2711
GB-1	CTRP2	8.1695	12.0626	6.8549	12.2143
SF126	CTRP2	8.2148	11.3766	7.2256	10.5954
ONS-76	CTRP2	8.2252	10.9123	7.453	9.6488
SNU-1105	CTRP2	8.3711	13.4802	6.3519	13.8087
DBTRG-05MG	CTRP2	8.3722	13.8597	6.1657	14.5589
GaMG	CTRP2; CTRP1	8.4011	11.6477	7.2755	9.9512
Becker	CTRP2	8.4139	10.8422	7.6721	8.2992
SF295	CTRP2; CTRP1	8.4301	9.6472	8.2156	6.0988
LN-18	CTRP2	8.4573	9.0071	8.4354	5.2097
U-251MG	CTRP2	8.467	12.2391	7.0496	10.7316
LN-229	CTRP2; CTRP1	8.4692	9.0639	8.4383	5.1614
SNU-201	CTRP2	8.4943	9.6024	8.3014	5.5915
CAS-1	CTRP2	8.5003	9.1711	8.4487	5.0277
M059K	CTRP2	8.5262	9.1595	8.4797	4.8374
U-118MG	CTRP2	8.5545	9.4975	8.4054	5.0273
Hs 683	CTRP2	8.5555	9.1647	8.5104	4.6376
CCF-STTG1	CTRP2	8.5713	9.1228	8.5371	4.4939
42-MG-BA	CTRP2	8.5776	12.5491	6.9989	10.6961
SNU-489	CTRP2	8.584	10.2003	8.1385	5.9956
DK-MG	CTRP2	8.5939	9.1898	8.5462	4.3915
SNU-626	CTRP2	8.6239	9.1503	8.5884	4.1487
GMS-10	CTRP2	8.6334	20.1643	3.2573	24.0831
U-87MG ATCC	CTRP2	8.6411	16.4854	5.0998	18.0939
GOS-3	CTRP2	8.6712	10.4063	8.1289	5.8199
YKG-1	CTRP2	8.6814	9.2985	8.611	3.8922
KG-1-C	CTRP2	8.8293	9.2044	8.7993	2.7634
SNB-75	CTRP2	8.8326	12.8007	7.1028	9.7189
YH-13	CTRP2	9.6615	16.9641	5.7156	13.7292
A-172	CTRP2	9.6644	17.299	5.5507	14.3573
KNS-81	CTRP2	9.9339	11.1795	8.7596	0.9557
-----------


⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HEC-265	CTRP2; CTRP1	5.5777	6.8148	5.576	24.3063
HEC-50B	CTRP2	5.7034	7.2106	5.6954	23.491
HEC-151	CTRP2; CTRP1	5.9297	8.1657	5.853	22.218
JHUEM-1	CTRP2	7.015	9.0138	6.868	15.2434
HEC-1-A	CTRP2	7.1279	9.4141	6.8829	14.8462
HEC-251	CTRP2; CTRP1	7.1322	9.2191	6.9433	14.6144
RL95-2	CTRP2	7.1447	9.6489	6.8272	15.0014
JHUEM-2	CTRP2; CTRP1	7.1687	9.1269	7.0075	14.2721
KLE	CTRP2; CTRP1	7.3177	9.3979	7.0947	13.5056
HEC-1-B	CTRP2	7.3532	9.8028	7.0007	13.749
HEC-59	CTRP2; CTRP1	7.4263	9.6751	7.1239	13.0773
HEC-6	CTRP2; CTRP1	7.7631	9.3623	7.5909	10.362
AN3-CA	CTRP2	7.9087	11.8792	6.6896	13.5086
JHUEM-7	CTRP2	7.9247	10.2116	7.4544	10.4202
HEC-108	CTRP2; CTRP1	7.9426	10.9066	7.1718	11.4872
JHUEM-3	CTRP2	8.3725	11.5177	7.3108	9.873
ESS-1	CTRP2	8.3763	9.6753	8.1473	6.5096
MFE-296	CTRP2	8.4371	11.8699	7.2018	10.1713
EFE-184	CTRP2	8.4604	12.0631	7.1295	10.4167
EN	CTRP2	8.4911	14.2059	6.1016	14.5563
MFE-319	CTRP2; CTRP1	8.8629	14.7508	6.1572	13.547
Ishikawa (Heraklio) 02 ER-	CTRP2; CTRP1	7.3914	9.2563	7.2161	12.8428
-----------


⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
UO-31	CTRP2	6.5196	9.5277	6.1855	19.2102
KMRC-20	CTRP2	7.4781	9.7898	7.1401	12.8669
SNU-1272	CTRP2	7.6028	9.8423	7.2557	12.0756
VMRC-RCZ	CTRP2	7.7993	11.0353	6.9687	12.6623
786-O	CTRP2	7.8265	10.5142	7.2247	11.5801
TUHR14TKB	CTRP2	7.967	14.4437	5.5073	33.5509
RCC10RGB	CTRP2; CTRP1	8.0838	9.5793	7.8686	8.3936
VMRC-RCW	CTRP2; CTRP1	8.2644	11.3298	7.296	10.1894
TUHR10TKB	CTRP2	8.2903	9.4401	8.14	6.7823
769-P	CTRP2	8.3369	11.6362	7.2199	10.3288
CAL-54	CTRP2	8.3578	11.4452	7.3315	9.8226
KMRC-1	CTRP2	8.4795	13.7289	6.3274	13.6697
KMRC-2	CTRP2	8.4985	12.0694	7.1618	10.1973
A-498	CTRP2	8.5117	10.0063	8.152	6.1266
Caki-2	CTRP2	8.5757	12.8623	6.8427	11.3465
KMRC-3	CTRP2	8.6263	9.8223	8.35	5.0449
BFTC-909	CTRP2	8.7343	9.6041	8.5549	3.9556
ACHN	CTRP2	8.8651	12.4787	7.2917	8.8628
OS-RC-2	CTRP2	9.8527	22.6177	3.047	22.2506
Caki-1	CTRP2	12.1476	20.774	5.6701	9.895
-----------


⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 51 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SW480	CTRP1	5.4534	9.4295	5.0482	52.7321
SNU-C1	CTRP2	5.7056	7.6091	5.6764	23.5473
SW620	CTRP2; CTRP1	6.0267	8.4919	5.9044	21.7302
SNU-407	CTRP2	6.4691	8.3244	6.4072	18.5776
SNU-175	CTRP1	6.5697	9.4304	6.2654	39.3687
GP2d	CTRP2; CTRP1	6.601	8.7625	6.4736	17.9277
CW-2	CTRP2; CTRP1	6.6472	8.9863	6.4737	17.7834
SNU-C5	CTRP2; CTRP1	6.74	9.5087	6.4314	17.6542
SW403	CTRP1	6.8191	9.6307	4.1524	4.5514
SNU-81	CTRP1	6.8206	10.2032	6.2767	37.2791
SNU-C4	CTRP2; CTRP1	6.8865	9.0062	6.7297	16.1328
NCI-H747	CTRP2	7.0056	10.9628	6.1795	17.8492
LoVo	CTRP2; CTRP1	7.0621	9.5168	6.7798	15.4198
LS123	CTRP2; CTRP1	7.1399	8.7802	7.0541	14.1971
SW1417	CTRP2	7.2066	9.8819	6.8144	14.869
T84	CTRP2	7.278	9.3865	7.0548	13.7699
MDST8	CTRP2; CTRP1	7.2918	9.0557	7.1595	13.3506
SNU-61	CTRP2; CTRP1	7.4572	9.5736	7.1914	12.7367
LS180	CTRP2; CTRP1	7.5926	10.0792	7.1558	12.4833
HT-55	CTRP2; CTRP1	7.6128	9.3366	7.4346	11.3824
SNU-C2A	CTRP2; CTRP1	7.613	10.6961	6.9254	13.3196
HCT 15	CTRP2	7.6388	9.7901	7.3134	11.7553
CL-11	CTRP2	7.8716	10.7205	7.1819	11.6299
HCT 116	CTRP2; CTRP1	7.9067	11.3946	6.9134	12.6121
COLO201	CTRP2	7.9853	16.9734	4.277	22.4017
COLO 678	CTRP2; CTRP1	7.997	11.1712	7.1063	11.612
SNU-1040	CTRP1	8.0247	10.3159	7.5075	21.017
RKO	CTRP2; CTRP1	8.0678	9.3333	7.9317	8.2069
SW948	CTRP2; CTRP1	8.0693	10.1304	7.6396	9.3101
SK-CO-1	CTRP2; CTRP1	8.1487	10.1296	7.723	8.7712
NCI-H716	CTRP2	8.1647	10.653	7.5107	9.5687
KM12	CTRP1	8.1688	9.7242	7.901	16.9564
OUMS-23	CTRP2	8.1791	9.8326	7.8761	8.096
SW48	CTRP2; CTRP1	8.2149	10.6351	7.5695	9.2062
HT115	CTRP2; CTRP1	8.2173	9.3388	8.093	7.1711
COLO205	CTRP2; CTRP1	8.2274	9.9891	7.8639	8.0107
RCM-1 [Human ESC]	CTRP2; CTRP1	8.2846	10.5142	7.6946	8.5293
NCI-H508	CTRP1	8.4057	9.42	8.267	12.5473
HCT 8	CTRP2; CTRP1	8.4296	9.0609	8.396	5.4343
COLO 320	CTRP2; CTRP1	8.433	11.7673	7.2477	9.9918
HCC-56	CTRP2	8.4489	9.2125	8.382	5.4242
LS1034	CTRP2	8.4656	10.6343	7.8202	7.5729
CL-34	CTRP1	8.4839	9.47	8.3338	11.5266
C2BBe1	CTRP2; CTRP1	8.4939	10.6631	7.8346	7.445
LS411N	CTRP2; CTRP1	8.4973	9.0863	8.4644	4.9814
LS513	CTRP2; CTRP1	8.5002	10.6067	7.8672	7.2973
DLD-1	CTRP2; CTRP1	8.5595	9.1746	8.5124	4.6181
SNU-503	CTRP2	8.5661	13.6056	6.4663	12.9159
SNU-1033	CTRP2	8.635	26.2025	0.2422	30.7948
HT-29	CTRP2; CTRP1	8.7668	9.2381	8.722	3.2319
CL-40	CTRP1	8.9898	9.9662	8.6354	6.161
-----------


⏷ Show the Full List of 51 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuH-6	CTRP2	5.4734	9.3569	5.0947	26.3024
PLC/PRF/5	CTRP2	6.6596	9.6967	6.2845	18.4318
Li-7	CTRP2	6.9492	12.0728	5.6411	20.063
Hep 3B2.1-7	CTRP2	7.1129	9.2599	6.9111	14.7889
JHH-4	CTRP2	7.1473	9.5326	6.8675	14.8447
JHH-5	CTRP2	7.1837	10.0104	6.7436	15.2007
JHH-2	CTRP2	7.2795	10.037	6.8367	14.5769
SNU-423	CTRP2	7.7528	10.3044	7.2356	11.7352
SNU-182	CTRP2	7.7561	10.3327	7.2274	11.7578
Hep-G2	CTRP2; CTRP1	7.8025	10.2781	7.2986	11.3558
SNU-761	CTRP2	8.0202	10.4506	7.4525	10.1731
SNU-398	CTRP2; CTRP1	8.1385	9.2116	8.0435	7.5882
SNU-475	CTRP2	8.3559	12.4784	6.8295	11.8887
SNU-387	CTRP2	8.3602	13.1004	6.5287	13.1123
JHH-1	CTRP2	8.4208	11.5195	7.356	9.5747
SNU-449	CTRP2; CTRP1	8.4266	11.9751	7.1408	10.4468
SK-HEP-1	CTRP2	8.4778	11.1333	7.5959	8.4571
HuH-1	CTRP2	8.5051	9.2704	8.4273	5.0902
HLF	CTRP2	9.2395	13.6377	7.0333	9.192
JHH-6	CTRP2; CTRP1	10.2784	11.0892	8.9625	0.1389
-----------


⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 156 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H1184	CTRP2	2.5201	4.5149	0.4719	2.7272
SW1573	CTRP2	4.5443	9.9237	3.9111	33.1849
NCI-H1341	CTRP2	5.4803	7.523	5.4479	25.0576
KNS-62	CTRP2; CTRP1	5.7045	6.8485	5.7033	23.4612
SBC-5	CTRP2	5.7804	6.2939	5.7804	22.9514
NCI-H211	CTRP2	5.8481	9.2364	5.5373	23.5822
NCI-H524	CTRP2	5.9647	8.2804	5.8736	22.0346
NCI-H1963	CTRP1	5.9733	10.4478	5.2761	47.3792
DMS 53	CTRP2	6.0178	9.2358	5.7226	22.4001
NCI-H82	CTRP1	6.018	8.714	4.0766	7.279
HCC1195	CTRP2; CTRP1	6.0459	8.3983	5.9416	21.5403
NCI-H1048	CTRP1	6.256	7.9562	4.579	2.542
NCI-H889	CTRP2	6.3707	8.1849	6.3204	19.1928
NCI-H446	CTRP2	6.4083	10.7153	5.6473	21.5235
EPLC-272H	CTRP2; CTRP1	6.4146	9.3317	6.1289	19.7313
HCC33	CTRP1	6.4835	8.1341	4.6228	1.8072
NCI-H1581	CTRP2	6.5024	8.9051	6.3352	18.7239
COR-L88	CTRP2; CTRP1	6.5075	9.4687	6.1902	19.2294
HCC44	CTRP2; CTRP1	6.552	9.0449	6.3557	18.4975
NCI-H1573	CTRP2; CTRP1	6.6715	11.4256	5.6366	20.8275
LXF 289	CTRP2; CTRP1	6.6946	9.0134	6.5188	17.4763
RERF-LC-A1	CTRP2	6.806	9.9601	6.3543	17.7453
NCI-H2286	CTRP1	6.8069	8.2481	4.7267	0.7864
NCI-H1568	CTRP2; CTRP1	6.8181	9.1275	6.6249	16.7174
NCI-H1092	CTRP2	6.8248	16.0728	3.6429	27.1817
NCI-H1703	CTRP2	6.8307	9.644	6.4876	17.1788
NCI-H1437	CTRP1	6.86	9.4911	4.2374	3.8315
COLO 668	CTRP2; CTRP1	6.9103	9.3073	6.6767	16.2504
Lu-65	CTRP2; CTRP1	6.9393	10.0412	6.4693	16.931
DMS 454	CTRP2	6.9457	9.4911	6.6609	16.2014
COR-L279	CTRP1	6.9552	8.6677	4.6288	1.1262
RERF-LC-KJ	CTRP1	6.9879	9.1787	4.4379	2.2101
RERF-LC-MS	CTRP2	7.0124	9.5212	6.7242	15.7712
NCI-H520	CTRP2	7.0144	10.0771	6.537	16.4616
NCI-H146	CTRP2	7.0156	10.0771	6.5384	16.4531
NCI-H647	CTRP2	7.029	9.2295	6.8279	15.3439
NCI-H1944	CTRP2; CTRP1	7.0297	9.8158	6.6463	16.0086
NCI-H661	CTRP2; CTRP1	7.0379	10.4781	6.4099	16.8773
LCLC-97TM1	CTRP1	7.046	10.5994	3.8476	6.3377
NCI-H841	CTRP2; CTRP1	7.1054	9.7034	6.7665	15.3411
NCI-H2029	CTRP2; CTRP1	7.1224	9.3343	6.9004	14.7994
NCI-H1930	CTRP1	7.1368	8.6693	4.7043	0.6096
NCI-H2081	CTRP2; CTRP1	7.1725	10.9634	6.3538	16.7249
NCI-H1155	CTRP2	7.2004	9.3674	6.9758	14.2907
NCI-H1666	CTRP2; CTRP1	7.2416	10.3751	6.6667	15.33
NCI-H1836	CTRP1	7.253	9.7487	6.9061	30.4257
Calu-6	CTRP2; CTRP1	7.3024	8.7506	7.2351	13.0513
CAL-12T	CTRP2; CTRP1	7.3207	8.981	7.2085	13.0874
PC-14	CTRP2	7.3252	9.4915	7.0741	13.5584
DV-90	CTRP2; CTRP1	7.353	10.6182	6.6864	14.9486
NCI-H2106	CTRP2	7.3685	9.326	7.1712	13.0748
NCI-H460	CTRP2; CTRP1	7.4	8.5116	7.3735	12.2612
COR-L51	CTRP2; CTRP1	7.4511	9.6353	7.1643	12.8551
NCI-H810	CTRP2; CTRP1	7.4786	9.6061	7.2038	12.628
DMS 79	CTRP2	7.4805	13.4868	5.5115	19.203
SCLC-21H	CTRP1	7.4936	9.9712	7.0851	27.5449
NCI-H727	CTRP2; CTRP1	7.5071	9.8253	7.1589	12.7132
NCI-H2342	CTRP2; CTRP1	7.5233	10.048	7.0938	12.9134
NCI-H2172	CTRP2; CTRP1	7.5342	12.3394	6.1059	16.7619
NCI-H1876	CTRP1	7.5351	10.0931	7.0828	27.2912
NCI-H2085	CTRP2	7.5381	11.3021	6.5839	14.8601
NCI-H1435	CTRP2; CTRP1	7.5394	9.4537	7.3191	12.0237
NCI-H1105	CTRP2; CTRP1	7.5611	9.6077	7.2928	12.057
NCI-H1563	CTRP2	7.5693	12.9828	5.8373	17.7296
NCI-H2228	CTRP2	7.6001	9.9685	7.206	12.2707
NCI-H1975	CTRP1	7.6009	9.2771	4.6643	0.464
SHP-77	CTRP2; CTRP1	7.6182	11.5941	6.5333	14.8561
NCI-H1355	CTRP2; CTRP1	7.6283	9.9105	7.258	11.9943
VMRC-LCD	CTRP2; CTRP1	7.6573	10.8378	6.9104	13.2613
NCI-H522	CTRP2; CTRP1	7.6644	10.6394	7.003	12.8793
NCI-H23	CTRP2; CTRP1	7.669	10.8835	6.9025	13.2619
EBC-1	CTRP2; CTRP1	7.7052	10.0302	7.2947	11.6383
NCI-H1755	CTRP2; CTRP1	7.7514	9.3257	7.589	10.404
NCI-H1793	CTRP2; CTRP1	7.7978	10.3981	7.2439	11.5813
NCI-H1694	CTRP2; CTRP1	7.8051	9.8675	7.4636	10.7154
NCI-H596	CTRP1	7.8113	9.3951	7.6291	21.3524
NCI-H838	CTRP2	7.813	10.8627	7.0594	12.267
SK-MES-1	CTRP2	7.8397	10.6499	7.1799	11.7211
HCC2279	CTRP2	7.844	10.9373	7.0579	12.1932
A-549	CTRP2; CTRP1	7.8644	10.3021	7.3537	10.9747
HOP-62	CTRP2	7.8645	12.4754	6.3643	14.926
NCI-H2122	CTRP2; CTRP1	7.8865	9.2532	7.7572	9.3865
NCI-H2405	CTRP2; CTRP1	7.8939	11.5176	6.8438	12.9236
NCI-H2196	CTRP2	7.9157	9.7897	7.6112	9.843
HCC4006	CTRP2; CTRP1	7.9285	11.2752	6.9901	12.2499
HCC1833	CTRP2; CTRP1	7.9315	9.8496	7.6056	9.8197
NCI-H2073	CTRP1	7.9407	11.1558	7.0482	25.045
COLO 699	CTRP2; CTRP1	7.9558	10.0753	7.5428	9.9931
DMS 114	CTRP2	7.9977	10.283	7.5009	10.0427
T3M-10	CTRP2; CTRP1	8.0086	11.2345	7.0887	11.6536
HCC15	CTRP2; CTRP1	8.0103	9.8797	7.6782	9.3223
NCI-H1339	CTRP2	8.0149	10.9497	7.2253	11.0896
LOU-NH91	CTRP2	8.066	10.6941	7.3922	10.2936
SK-LU-1	CTRP2; CTRP1	8.0671	9.6898	7.8108	8.6586
Calu-3	CTRP2; CTRP1	8.0796	10.0579	7.6803	9.1237
NCI-H1792	CTRP2; CTRP1	8.0987	10.3566	7.5742	9.4875
HCC2108	CTRP2; CTRP1	8.175	12.6695	6.567	13.3762
HCC366	CTRP2	8.1977	10.6045	7.5659	9.2644
NCI-H1650	CTRP2	8.1988	11.6209	7.0943	11.1684
HCC827	CTRP2; CTRP1	8.2205	10.1832	7.7749	8.3769
COR-L105	CTRP2	8.2344	12.346	6.78	12.3695
HARA [Human squamous cell lung carcinoma]	CTRP2; CTRP1	8.2378	11.7457	7.0723	11.1654
NCI-H441	CTRP2; CTRP1	8.248	10.7474	7.5516	9.195
HCC1588	CTRP2	8.2557	9.5032	8.081	7.1029
COR-L95	CTRP2	8.2679	10.2269	7.805	8.1337
DMS 273	CTRP2; CTRP1	8.2833	10.6731	7.621	8.8276
NCI-H1395	CTRP2	8.2842	10.9849	7.4777	9.4035
NCI-H1373	CTRP2; CTRP1	8.2856	11.4032	7.2818	10.1965
LK2	CTRP2	8.2862	9.4423	8.1348	6.8138
LCLC-103H	CTRP2; CTRP1	8.2926	9.5764	8.0948	6.9447
NCI-H1693	CTRP2	8.3018	9.8784	7.9876	7.329
NCI-H2023	CTRP2; CTRP1	8.3086	9.8415	8.0098	7.2248
EKVX	CTRP2	8.3145	12.1118	6.969	11.4103
LUDLU-1	CTRP2	8.3202	10.3139	7.8204	7.9369
NCI-H2126	CTRP2; CTRP1	8.3266	9.7375	8.0702	6.9429
NCI-H1299	CTRP2; CTRP1	8.3347	11.3699	7.3452	9.8211
HCC2935	CTRP2; CTRP1	8.3392	9.7656	8.0725	6.8989
NCI-H1651	CTRP2	8.3403	14.2454	5.9464	15.5058
NCI-H1915	CTRP2; CTRP1	8.3468	10.9695	7.5465	8.972
NCI-H1838	CTRP2	8.355	10.6565	7.7002	8.3301
NCI-H292	CTRP2	8.381	10.295	7.8907	7.5009
NCI-H3255	CTRP1	8.3968	9.8911	8.0748	14.1784
LC-1/sq-SF	CTRP2; CTRP1	8.3975	11.2698	7.4534	9.2299
HCC78	CTRP2; CTRP1	8.444	9.8932	8.1305	6.3896
NCI-H650	CTRP2; CTRP1	8.4662	11.7669	7.2791	9.7865
NCI-H2009	CTRP2; CTRP1	8.48	10.5952	7.8527	7.4059
NCI-H2170	CTRP2	8.4939	11.5383	7.4162	9.1581
HCC95	CTRP2	8.4999	10.2289	8.0409	6.5987
NCI-H196	CTRP2	8.5065	9.6011	8.3148	5.5066
NCI-H2444	CTRP2	8.5298	9.2218	8.4678	4.8689
NCI-H1623	CTRP2	8.5346	13.0278	6.7237	11.9274
IA-LM	CTRP2	8.5627	9.7756	8.3038	5.3949
NCI-H2141	CTRP1	8.5673	9.1739	8.518	9.5417
HCC1359	CTRP1	8.5696	9.0563	8.5463	9.3114
RERF-LC-Ad2	CTRP2	8.5704	14.2391	6.1559	14.1671
ChaGo-K-1	CTRP2; CTRP1	8.5765	12.3712	7.0856	10.3392
NCI-H322	CTRP2	8.5803	9.8677	8.2829	5.4304
HOP-92	CTRP2	8.5837	19.2764	3.6578	23.0241
NCI-H1781	CTRP1	8.586	9.8232	8.3003	11.2037
NCI-H358	CTRP2; CTRP1	8.6043	10.3434	8.0927	6.1297
NCI-H1869	CTRP2	8.6362	10.0166	8.2744	5.3194
NCI-H526	CTRP2	8.6378	9.2987	8.5635	4.1962
Sq-1	CTRP1	8.6529	9.2124	8.6012	8.3389
MOR/CPR	CTRP2	8.7348	9.9136	8.4205	4.4848
Calu-1	CTRP2	8.7454	9.3419	8.6666	3.4987
NCI-H226	CTRP2	8.7543	9.3471	8.6744	3.4437
Lu-99	CTRP2; CTRP1	8.7754	9.7224	8.5471	3.877
COR-L23	CTRP1	8.7973	9.2567	8.7459	6.2771
SW1271	CTRP2	8.7982	11.9351	7.502	8.1267
BEN	CTRP2; CTRP1	8.8453	9.1676	8.8253	2.6214
NCI-H2110	CTRP2; CTRP1	8.8662	13.7468	6.661	11.4833
NCI-H2030	CTRP2; CTRP1	8.995	12.8224	7.2336	8.8382
RERF-LC-Ad1	CTRP2	9.0342	9.8058	8.7655	2.3565
HCC1171	CTRP2	9.7585	15.3172	6.614	9.9646
HCC1438	CTRP2	9.9722	16.0343	6.424	10.3602
Hs 888.Lu	CTRP2	8.566	9.6531	8.3575	5.1778
-----------


⏷ Show the Full List of 156 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	8.0143	9.8044	7.7113	9.1849
TOV-21G	CTRP2	4.9877	5.7751	4.9877	28.2274
MCAS	CTRP2	5.8783	7.6969	5.8499	22.3952
A2780	CTRP2; CTRP1	6.2673	9.0307	6.0487	20.4693
OVMANA	CTRP1	6.2931	7.5985	4.7515	1.2698
RMUG-S	CTRP1	6.4488	11.2213	5.4814	42.9907
FU-OV-1	CTRP2	6.5464	11.0177	5.674	21.0342
JHOS-4	CTRP1	6.5579	8.5034	4.5041	2.4943
COV318	CTRP1	6.6444	7.4534	4.9505	0.1057
OVCAR-8	CTRP2; CTRP1	6.9288	9.9289	6.4979	16.8542
OV-90	CTRP2; CTRP1	7.0004	10.0603	6.5281	16.5352
TYK-nu	CTRP2; CTRP1	7.1379	9.3439	6.9145	14.7011
DOV13	CTRP2	7.2694	10.245	6.7471	14.9453
IGROV-1	CTRP2; CTRP1	7.327	9.8524	6.9549	13.9961
JHOM-1	CTRP2; CTRP1	7.3771	9.0482	7.2543	12.7499
COV434	CTRP2; CTRP1	7.4139	10.3262	6.8689	14.0777
JHOC-5	CTRP2; CTRP1	7.4559	9.2138	7.298	12.3514
HEY A8	CTRP2; CTRP1	7.4971	9.6177	7.2201	12.5135
RMG-I	CTRP2; CTRP1	7.5107	11.8526	6.3075	16.0242
OVK18	CTRP2; CTRP1	7.567	9.9519	7.1768	12.4749
ES2	CTRP2	7.5804	9.9729	7.1833	12.4127
OVTOKO	CTRP2	7.626	9.9532	7.2395	12.071
OVKATE	CTRP1	7.6766	10.8572	6.9139	27.5868
OVCAR-4	CTRP2; CTRP1	7.7207	10.9023	6.9474	12.95
Caov-3	CTRP2; CTRP1	7.9119	9.1003	7.8246	9.0673
OAW28	CTRP2	7.9196	11.2835	6.9774	12.323
SNU-119	CTRP2	8.2589	9.6367	8.0364	7.2612
Kuramochi	CTRP2	8.2627	11.3044	7.3064	10.1515
OVSAHO	CTRP2	8.2757	9.6028	8.067	7.0981
EFO-27	CTRP2; CTRP1	8.2812	10.2305	7.8171	8.0515
TOV-112D	CTRP2	8.2858	11.2407	7.3591	9.8813
SNU-8	CTRP2	8.3385	10.7603	7.6359	8.6303
SK-OV-3	CTRP2; CTRP1	8.373	11.0058	7.555	8.8739
OVCAR-5	CTRP2	8.373	10.3425	7.8613	7.639
ONCO-DG-1	CTRP2	8.3852	9.6868	8.1524	6.4653
COV644	CTRP2; CTRP1	8.4024	9.6473	8.186	6.2888
OVISE	CTRP2	8.4702	11.9829	7.1777	10.1956
EFO-21	CTRP2; CTRP1	8.5025	11.2748	7.5516	8.581
JHOS-2	CTRP2	8.5072	10.4383	7.9524	6.936
OV56	CTRP2	8.5335	9.7932	8.2659	5.6214
COV362	CTRP2; CTRP1	8.6224	10.4052	8.0817	6.1298
OC 314	CTRP2	8.6729	12.7299	6.9958	10.5023
OV7	CTRP2; CTRP1	8.7649	10.173	8.3305	4.774
OAW42	CTRP2; CTRP1	8.773	9.0805	8.7626	3.0692
SNU-840	CTRP2; CTRP1	9.0074	14.1226	6.5951	11.4676
-----------


⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
H-STS	CTRP2	8.1315	10.4652	7.5606	9.4553
SYO-1	CTRP2	8.6282	9.2633	8.5636	4.2245
-----------

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-CH1	CTRP2	8.5388	9.8148	8.2624	5.6209
-----------

Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Yamato-SS	CTRP2	8.5852	9.1977	8.5347	4.4595
Aska-SS	CTRP2	8.7571	9.2514	8.7077	3.3129
Rh41	CTRP2	5.487	7.751	5.4338	25.0838
G-401	CTRP2; CTRP1	6.9714	10.3301	6.3963	17.1152
TTC-709	CTRP2	7.1221	10.121	6.6365	15.7802
HT-1080	CTRP2; CTRP1	7.2663	10.0905	6.8025	14.7435
TE 617.T	CTRP2	7.291	10.4622	6.6845	15.1256
A-204	CTRP2	7.4601	11.2773	6.5154	15.3326
G-402	CTRP2	7.7952	11.5377	6.7364	13.6001
RKN	CTRP2; CTRP1	7.8525	11.0274	7.0262	12.2971
GCT	CTRP2	7.8778	12.2002	6.5079	14.3164
KYM-1	CTRP2	8.0917	10.6097	7.456	9.9733
MES-SA	CTRP2	8.3912	10.3028	7.8976	7.4476
Hs 729.T	CTRP2	8.4264	9.6291	8.2186	6.0975
TE 441.T	CTRP2	8.462	9.6908	8.2324	5.9457
SK-UT-1	CTRP2	8.4943	17.2279	4.6019	20.1777
SK-LMS-1	CTRP2	8.557	12.0081	7.2461	9.718
Tm87-16	CTRP2	8.6752	9.1869	8.6356	3.8222
BT-12	CTRP2	8.7154	9.067	8.7029	3.4595
BT-16	CTRP2	8.766	9.2883	8.7063	3.2915
SW982	CTRP2	8.8029	9.2959	8.7441	3.0434
RD	CTRP2	11.0371	20.545	4.9979	13.9867
-----------


⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MSTO-211H	CTRP1	7.0677	9.6672	4.2724	3.1826
ACC-MESO-1	CTRP2	7.813	10.4058	7.2565	11.4914
NCI-H2452	CTRP2	8.1297	10.7858	7.4154	10.0388
NCI-H2052	CTRP2; CTRP1	8.1475	10.7024	7.471	9.771
NCI-H28	CTRP2; CTRP1	8.2751	10.3913	7.74	8.3728
MPP 89	CTRP2	8.3318	9.8263	8.0404	7.0432
IST-Mes1	CTRP2	8.4702	14.236	6.0679	14.7368
JL-1	CTRP2	8.5732	9.4424	8.4454	4.823
-----------


⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LNCaP clone FGC	CTRP2	6.6971	8.8608	6.5569	17.3336
NCI-H660	CTRP2	6.7845	9.6954	6.4207	17.5616
22Rv1	CTRP2	7.3613	10.481	6.7512	14.6757
VCaP	CTRP2	7.4923	10.3167	6.9557	13.5283
DU145	CTRP2	8.1866	11.0573	7.3475	10.1699
PaCa-3	CTRP2; CTRP1	8.4243	10.0066	8.0618	6.7114
-----------


⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-253	CTRP2	7.8404	11.4741	6.8107	13.1895
YD-15	CTRP2	8.4035	9.2602	8.3193	5.7884
-----------

Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ECC10	CTRP2	4.8624	8.0416	4.7273	29.5157
23132/87	CTRP2	5.9107	9.2079	5.6134	23.1188
Fu97	CTRP2; CTRP1	6.2702	8.244	6.2058	19.9098
SNU-16	CTRP2	6.8114	8.8451	6.6846	16.526
GSS	CTRP2	6.8383	8.3601	6.7957	16.0543
HGC-27	CTRP2	6.8457	8.5714	6.7735	16.1071
SNU-1	CTRP2	6.9179	9.4441	6.6449	16.3429
NCI-N87	CTRP2	7.1741	10.4564	6.563	15.9142
SNU-620	CTRP2	7.2514	9.0555	7.1155	13.6321
NUGC-4	CTRP2; CTRP1	7.2786	10.3167	6.729	14.9891
MKN74	CTRP2; CTRP1	7.5463	10.302	7.0188	13.1366
SNU-601	CTRP2	7.7214	9.8817	7.3686	11.3116
HuG1-N	CTRP2	7.7781	9.8393	7.4451	10.8615
KE-39	CTRP2	7.8461	12.0649	6.5409	14.2602
MKN7	CTRP2; CTRP1	8.1517	11.1894	7.2516	10.6433
SNU-216	CTRP2	8.2611	11.0591	7.4202	9.6929
SNU-668	CTRP2	8.3253	9.8204	8.0358	7.0786
Hs 746.T	CTRP2	8.3453	10.1477	7.9191	7.481
IM95	CTRP2	8.3521	16.692	4.7436	19.9961
AGS	CTRP2; CTRP1	8.3688	9.0524	8.3319	5.8504
KATO III	CTRP2	8.372	10.3012	7.8787	7.572
SNU-719	CTRP2	8.4451	12.3315	6.9842	11.0509
SH-10-TC	CTRP2; CTRP1	8.4735	11.3207	7.5019	8.853
NUGC-3	CTRP2	8.4787	16.6768	4.8626	19.2993
ECC12	CTRP2	8.5919	9.1299	8.558	4.3559
GSU	CTRP2	8.6084	8.9188	8.6049	4.1411
MKN45	CTRP2	8.6379	11.1267	7.7515	7.4459
LMSU	CTRP2	9.2675	14.0107	6.8701	9.8173
MKN1	CTRP2	9.9008	22.5404	3.1244	21.9455
SNU-1077	CTRP2	7.6996	10.3621	7.156	12.1879
SNG-M	CTRP2; CTRP1	7.711	10.629	7.0558	12.5483
SNU-685	CTRP2	8.5635	10.0341	8.1927	5.8308
-----------


⏷ Show the Full List of 32 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
8505C	CTRP2	7.7294	10.5946	7.0896	12.3672
8305C	CTRP2	7.7667	10.02	7.3642	11.2012
FTC-133	CTRP2	7.7892	10.953	6.995	12.5836
TT	CTRP2	7.8359	10.836	7.0946	12.068
B-CPAP	CTRP2	7.8792	11.3508	6.9062	12.7099
CGTH-W-1	CTRP2	8.3414	10.7967	7.6219	8.6796
SW579	CTRP2	8.4189	9.6548	8.2007	6.1864
FTC-238	CTRP2	8.4981	14.1232	6.1489	14.3514
BHT-101	CTRP2	8.5242	9.7026	8.2935	5.5396
TT2609-C02	CTRP2	8.5753	12.1094	7.2133	9.8129
ML-1 [Human leukemia]	CTRP2	8.6559	10.424	8.1057	5.9514
-----------


⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SCC-25	CTRP2	3.4127	16.6161	0.0164	43.767
HSC-2	CTRP2; CTRP1	5.4832	6.1944	5.4832	24.9296
HSC-4	CTRP2	5.6686	6.1099	5.6686	23.6958
Detroit 562	CTRP2	7.3656	9.5425	7.1019	13.3369
HSC-3	CTRP2	7.3926	10.3091	6.8531	14.1974
FaDu	CTRP2	7.5871	9.2604	7.4285	11.4821
SNU-1214	CTRP2	7.8948	9.825	7.5757	10.0365
YD-8	CTRP2	7.976	10.9445	7.1885	11.3355
SNU-46	CTRP2	8.1595	11.4107	7.1555	11.0138
BICR 22	CTRP2	8.2317	10.0627	7.8377	8.1012
SNU-899	CTRP2	8.2891	9.4612	8.1315	6.8175
BICR 31	CTRP2	8.3261	11.5068	7.2715	10.143
SNU-1066	CTRP2	8.4049	11.3085	7.4421	9.2586
SNU-1076	CTRP2	8.4209	13.0431	6.6126	12.6339
PE/CA-PJ34 (clone C12)	CTRP2	8.4404	9.9677	8.0951	6.5377
BHY	CTRP2	8.4497	10.4389	7.8948	7.3106
PE/CA-PJ49	CTRP2	8.494	11.7515	7.3128	9.5842
PE/CA-PJ15	CTRP2	8.4973	10.1111	8.091	6.4056
SNU-1041	CTRP2	8.5487	13.6669	6.4202	13.1419
CAL-33	CTRP2	8.5638	9.4845	8.4201	4.9454
BICR 16	CTRP2	8.613	9.4048	8.5017	4.4976
SCC-4	CTRP2	8.6627	9.1994	8.6188	3.9208
SCC-9	CTRP2; CTRP1	8.6641	10.1127	8.2588	5.3114
BICR 18	CTRP2	8.6849	9.4192	8.5742	4.0188
PE/CA-PJ41 (clone D2)	CTRP2	8.7247	9.2756	8.6652	3.5651
BICR 6	CTRP2	8.7628	9.1419	8.741	3.1765
CAL-27	CTRP2	9.0175	17.5812	4.8752	18.1203
BICR 56	CTRP2	9.1912	10.0003	8.8113	1.8273
-----------


⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
UM-UC-3	CTRP2; CTRP1	5.6424	6.8542	5.6408	23.8755
253J	CTRP2	5.6524	8.2525	5.5425	24.1775
UM-UC-1	CTRP2	6.8073	8.3919	6.7588	16.2811
JMSU-1	CTRP2	6.8877	9.4426	6.6125	16.5517
RT-4	CTRP2; CTRP1	7.1761	11.2765	6.2238	17.2197
KU-19-19	CTRP2	7.3023	8.6787	7.2469	13.0108
U-BLC1	CTRP2	7.3262	10.6324	6.6524	15.1529
HT-1197	CTRP2	7.5228	11.2918	6.5729	14.9431
5637	CTRP2; CTRP1	7.5798	12.42	6.1131	16.6204
RT-112	CTRP2	7.7334	9.9482	7.3563	11.3248
SCaBER	CTRP2	7.7401	9.3914	7.557	10.5548
BFTC-905	CTRP2	7.7616	9.0243	7.6784	10.0524
TCCSUP	CTRP2	7.8967	10.6669	7.2312	11.3695
VM-CUB-1	CTRP2	7.9729	11.2217	7.0591	11.8619
BC-3C	CTRP2	8.1124	10.2026	7.6544	9.1365
KMBC-2	CTRP2; CTRP1	8.1204	11.7809	6.9423	11.9743
253J-BV	CTRP2	8.2992	10.3566	7.78	8.1515
J82	CTRP2	8.5383	15.2892	5.6055	16.4097
647V	CTRP2	8.5619	12.8251	6.8485	11.3528
T24	CTRP2	8.5628	12.7853	6.869	11.2663
CAL-29	CTRP2	8.5668	9.5426	8.4016	5.0066
639V	CTRP2	8.6949	9.0849	8.6782	3.6103
HT-1376	CTRP2; CTRP1	8.7653	9.9291	8.4442	4.3133
-----------


⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HeLa	CTRP2	8.5005	9.0817	8.4687	4.9565
-----------

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Valdecoxib

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Diclofenac	DMPIHLS	Moderate	Increased risk of hepatotoxicity by the combination of Valdecoxib and Diclofenac.	Osteoarthritis [FA00-FA05]	[13]
-----------

Coadministration of a Drug Treating the Disease Different from Valdecoxib (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Valdecoxib and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[14]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Valdecoxib and Repaglinide.	Acute diabete complication [5A2Y]	[15]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Valdecoxib and Glibenclamide.	Acute diabete complication [5A2Y]	[15]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Valdecoxib and Tolazamide.	Acute diabete complication [5A2Y]	[16]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Valdecoxib and Nateglinide.	Acute diabete complication [5A2Y]	[15]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Valdecoxib and Glipizide.	Acute diabete complication [5A2Y]	[15]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Valdecoxib caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[17]
Metronidazole	DMTIVEN	Moderate	Decreased metabolism of Valdecoxib caused by Metronidazole mediated inhibition of CYP450 enzyme.	Amoebiasis [1A36]	[18]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Valdecoxib and Inotersen.	Amyloidosis [5D00]	[17]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Valdecoxib caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[19]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Valdecoxib and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[20]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Valdecoxib caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[14]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Budesonide.	Asthma [CA23]	[21]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Valdecoxib and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Valdecoxib and Kanamycin.	Bacterial infection [1A00-1C4Z]	[23]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Valdecoxib caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Valdecoxib caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Trovafloxacin	DM6AN32	Moderate	Additive CNS stimulant effects by the combination of Valdecoxib and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Sulfamethoxazole	DMB08GE	Moderate	Decreased metabolism of Valdecoxib caused by Sulfamethoxazole mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Valdecoxib and Streptomycin.	Bacterial infection [1A00-1C4Z]	[23]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Valdecoxib and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Valdecoxib and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[24]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Valdecoxib and ABT-492.	Bacterial infection [1A00-1C4Z]	[22]
Gentamicin	DMKINJO	Moderate	Increased risk of nephrotoxicity by the combination of Valdecoxib and Gentamicin.	Bacterial infection [1A00-1C4Z]	[23]
Levofloxacin	DMS60RB	Moderate	Additive CNS stimulant effects by the combination of Valdecoxib and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Tobramycin	DMUI0CH	Moderate	Increased risk of nephrotoxicity by the combination of Valdecoxib and Tobramycin.	Bacterial infection [1A00-1C4Z]	[23]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Valdecoxib caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[25]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Etidronic acid.	Bone paget disease [FB85]	[26]
Risedronate	DM5FLTY	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Risedronate.	Bone paget disease [FB85]	[26]
Alendronate	DMY2KX9	Moderate	Increased risk of nephrotoxicity by the combination of Valdecoxib and Alendronate.	Bone paget disease [FB85]	[26]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Valdecoxib and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[27]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Valdecoxib caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Valdecoxib and Drospirenone.	Contraceptive management [QA21]	[29]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Valdecoxib caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[30]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Valdecoxib caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[31]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Valdecoxib caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[32]
Aprepitant	DM053KT	Moderate	Increased metabolism of Valdecoxib caused by Aprepitant mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[33]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Valdecoxib caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[18]
Diazepam	DM08E9O	Moderate	Decreased metabolism of Valdecoxib caused by Diazepam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Primidone	DM0WX6I	Moderate	Increased metabolism of Valdecoxib caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Valdecoxib caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Valdecoxib caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Valdecoxib caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Valdecoxib caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Valdecoxib and Cannabidiol.	Epileptic encephalopathy [8A62]	[17]
Ethacrynic acid	DM60QMR	Moderate	Antagonize the effect of Valdecoxib when combined with Ethacrynic acid.	Essential hypertension [BA00]	[34]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Valdecoxib caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[18]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Valdecoxib caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[18]
Eplerenone	DMF0NQR	Moderate	Increased risk of hyperkalemia by the combination of Valdecoxib and Eplerenone.	Heart failure [BD10-BD1Z]	[35]
Chlorothiazide	DMLHESP	Moderate	Antagonize the effect of Valdecoxib when combined with Chlorothiazide.	Heart failure [BD10-BD1Z]	[34]
Furosemide	DMMQ8ZG	Moderate	Antagonize the effect of Valdecoxib when combined with Furosemide.	Heart failure [BD10-BD1Z]	[34]
Amiloride	DMRTSGP	Moderate	Antagonize the effect of Valdecoxib when combined with Amiloride.	Heart failure [BD10-BD1Z]	[34]
Bumetanide	DMRV7H0	Moderate	Antagonize the effect of Valdecoxib when combined with Bumetanide.	Heart failure [BD10-BD1Z]	[34]
Hydroflumethiazide	DMVPUQI	Moderate	Antagonize the effect of Valdecoxib when combined with Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[34]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Valdecoxib caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[36]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Valdecoxib and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[37]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Valdecoxib caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Valdecoxib caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Valdecoxib caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Valdecoxib caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Valdecoxib caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Fluvastatin	DM4MDJY	Moderate	Decreased metabolism of Valdecoxib caused by Fluvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[18]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Valdecoxib caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[14]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Valdecoxib and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[40]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Valdecoxib and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[41]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Valdecoxib and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[42]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Valdecoxib caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[18]
Indapamide	DMGN1PW	Moderate	Antagonize the effect of Valdecoxib when combined with Indapamide.	Hypertension [BA00-BA04]	[34]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Valdecoxib when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[43]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Valdecoxib caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[44]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[21]
Balsalazide	DM7I1T9	Moderate	Increased risk of nephrotoxicity by the combination of Valdecoxib and Balsalazide.	Indeterminate colitis [DD72]	[45]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Valdecoxib caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[46]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Valdecoxib caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[47]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Valdecoxib caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[48]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Valdecoxib and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[49]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Valdecoxib and Idelalisib.	Mature B-cell leukaemia [2A82]	[50]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Valdecoxib caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[51]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Valdecoxib and Clofarabine.	Mature B-cell lymphoma [2A85]	[17]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Valdecoxib caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[17]
Ethinyl estradiol	DMODJ40	Moderate	Decreased metabolism of Valdecoxib caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[52]
Danazol	DML8KTN	Moderate	Decreased metabolism of Valdecoxib caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[18]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Valdecoxib and Exjade.	Mineral absorption/transport disorder [5C64]	[53]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Deflazacort.	Muscular dystrophy [8C70]	[21]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Valdecoxib caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[17]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Valdecoxib caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[54]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Valdecoxib caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[18]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Valdecoxib caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[55]
Modafinil	DMYILBE	Minor	Increased metabolism of Valdecoxib caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[56]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Valdecoxib when combined with Polythiazide.	Oedema [MG29]	[34]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Valdecoxib caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[57]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Aspirin.	Pain [MG30-MG3Z]	[58]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Valdecoxib caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[59]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Valdecoxib caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[60]
Prednisone	DM2HG4X	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Prednisone.	Postoperative inflammation [1A00-CA43]	[21]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[21]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Valdecoxib caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[61]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Valdecoxib caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[62]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Valdecoxib and Everolimus.	Renal cell carcinoma [2C90]	[63]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Valdecoxib and Temsirolimus.	Renal cell carcinoma [2C90]	[63]
Gatifloxacin	DMSL679	Moderate	Additive CNS stimulant effects by the combination of Valdecoxib and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[24]
Sulfasalazine	DMICA9H	Moderate	Increased risk of nephrotoxicity by the combination of Valdecoxib and Sulfasalazine.	Rheumatoid arthritis [FA20]	[45]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Dexamethasone.	Rheumatoid arthritis [FA20]	[21]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Valdecoxib and Leflunomide.	Rheumatoid arthritis [FA20]	[41]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Valdecoxib caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[17]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Valdecoxib caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[14]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[21]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Valdecoxib and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Armodafinil	DMGB035	Minor	Increased metabolism of Valdecoxib caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[56]
LEE011	DMMX75K	Moderate	Decreased metabolism of Valdecoxib caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[64]
Prednisolone	DMQ8FR2	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[21]
Disulfiram	DMCL2OK	Moderate	Decreased metabolism of Valdecoxib caused by Disulfiram mediated inhibition of CYP450 enzyme.	Substance abuse [6C40]	[18]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Valdecoxib and Naltrexone.	Substance abuse [6C40]	[65]
Warfarin	DMJYCVW	Moderate	Decreased metabolism of Valdecoxib caused by Warfarin mediated inhibition of CYP450 enzyme.	Supraventricular tachyarrhythmia [BC81]	[18]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Valdecoxib caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[66]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Valdecoxib and Sirolimus.	Transplant rejection [NE84]	[63]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Valdecoxib and Tacrolimus.	Transplant rejection [NE84]	[63]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Valdecoxib and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[16]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Valdecoxib and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[16]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Valdecoxib and Olsalazine.	Ulcerative colitis [DD71]	[45]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Valdecoxib and Plazomicin.	Urinary tract infection [GC08]	[67]
Triamcinolone	DM98IXF	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[21]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Valdecoxib caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[18]
-----------


⏷ Show the Full List of 123 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2894).
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
6	Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003 Apr;98(4):853-61.
7	Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
8	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
9	Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
10	The effect of valdecoxib on the production of growth factors evoked by hypoxia and bacterial lipopolysaccharide in HMEC-1 cells. Adv Clin Exp Med. 2013 Nov-Dec;22(6):795-800.
11	Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
12	The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor. Eur J Clin Pharmacol. 2005 Jun;61(4):247-56.
13	Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
14	Cerner Multum, Inc. "Australian Product Information.".
15	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
16	Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
17	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18	Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
19	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
20	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
21	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
22	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
23	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
24	Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
25	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
26	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
27	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
28	Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
29	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
30	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
31	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
32	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
33	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
34	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
35	Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
36	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
37	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
38	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
39	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
40	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
41	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
42	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
43	McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
44	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
45	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
46	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
47	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
49	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
50	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
51	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
52	Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
53	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
54	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
55	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
56	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
57	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
58	Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
59	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
60	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
61	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
62	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
63	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
64	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
65	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
66	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
67	Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]